FDA Set to OK Genetically Altered Fish as Food
Next up: Bacon and pork chops from genetically modified "Enviropigs."
A fast growing genetically engineered salmon is a good bet for approval by the Food and Drug Administration. It would be the first genetically modified animal sold as food. Dubbed “Frankenfish” by opponents, the new version of Atlantic salmon was developed by AquaBounty Technologies. It grows almost twice as fast as farm-raised salmon, thanks to one growth hormone gene from a chinook salmon and another from an eel, the ocean pout. The application has been pending before the agency for well over 10 years.
A congressional effort to ban the fish will fail, although it’s a fair bet that lawmakers will give the FDA the authority to require a label identifying the produce as genetically modified. “Approval of genetically modified salmon, the first such hybrid to be considered for human consumption, is unprecedented, risky and a threat to the survival of wild species,” says Sen. Mark Begich, D-Alaska, whose state has a thriving salmon industry.
Also likely to be on the table: Broadening the mission of regulators to ensure they consider environmental risks before granting future approvals -- not just whether the food is safe and whether animals are harmed by the genetic manipulation.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
A push to add greater public input to the approval process is also a good bet. The current procedure is similar to that for new drugs, with limited public participation. “The current process is confidential. It’s not transparent or participatory,” says Gregory Jaffe of the Center for Science in the Public Interest.
Next up: The Enviropig -- a porker genetically altered to make the manure it produces less polluting, with phosphorus levels 30% to 65% lower than normal. It’s being developed by scientists at the University of Guelph in Canada. Also in the works from Hematech Inc. are cattle that are not susceptible to mad cow disease. The animals lack a protein that mutates, so they don’t get the disease and can’t pass it on.
Get Kiplinger Today newsletter — free
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.
-
Here's How To Get Organized And Work For Yourself
Whether you’re looking for a side gig or planning to start your own business, it has never been easier to strike out on your own. Here is our guide to navigating working for yourself.
By Laura Petrecca Published
-
How to Manage Risk With Diversification
"Don't put all your eggs in one basket" means different things to different investors. Here's how to manage your risk with portfolio diversification.
By Charles Lewis Sizemore, CFA Published
-
Europe Faces Economic and Political Headwinds Next Year
The Letter Challenges for Europe: Potential tariffs, high energy prices and more competition from China will weigh on the bloc in 2025.
By Rodrigo Sermeño Published
-
Don't Sleep on Japan's Economic Transformation
The Letter After almost three lost decades, Japan — one of the world's biggest economies — is finally showing signs of life.
By Rodrigo Sermeño Published
-
Kiplinger Outlook: Telecom Companies Brace for Tough Times
The Letter The telecom industry is entering a new era that threatens profitability. But the coming Trump administration will make it easier for the major players to adjust.
By John Miley Published
-
Start-ups Trying to (Profitably) Solve the World’s Hardest Problems
The Letter More investors are interested in companies working on breakthrough science to tackle huge societal challenges. The field of deep tech has major tailwinds, too.
By John Miley Published
-
The Big Questions for AR’s Future
The Letter As Meta shows off a flashy AR prototype, Microsoft quietly stops supporting its own AR headset. The two companies highlight the promise and peril of AR.
By John Miley Published
-
China's Economy Faces Darkening Outlook
The Letter What the slowdown in China means for U.S. businesses.
By Rodrigo Sermeño Published
-
AI Start-ups Keep Scoring Huge Sums
The Kiplinger Letter Investors continue to make bigger bets on artificial intelligence start-ups, even for small teams with no revenue. Some backers think a startling tech breakthrough is near.
By John Miley Published
-
Should We Worry About the Slowing U.S. Economy
The Letter With the labor market cooling off and financial markets turning jittery, just how healthy is the economy right now?
By David Payne Published